In a rat model of SNL, intrathecal administration of exendin-4 significantly alleviated pain-induced hippocampal neuroinflammation and enhanced cognitive recovery [68]
This contributes to dehydration and electrolyte imbalances both well-established triggers for headaches
The combined effect of these modifications increase the drugs half-life from minutes to approximately 168 hours, enabling its once-weekly injection schedule an enormous improvement compared to the twice daily injection required for exenatide (Byetta) which was the first GLP-1 drug that was launched.1 Semaglutide (under the brand names Ozempic and Wegovy) swept the market
The proliferation process is restored, inflammation is alleviated
Morley concludes, With expected drug sales for GLP1Rs in obesity estimated to surpass $126 billion by 2030, this drug category presents a lucrative market for drug developers
Metabolic Health First When used at low doses, GLP-1s help correct blood sugar instability and insulin resistance even before any weight loss occurs
.jpg)
